Gamelin Erick's Insider Trades & SAST Disclosures
Gamelin Erick's most recent trade in Acrivon Therapeutics Inc was a trade of 403 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gamelin Erick.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 14 May 2025 | 403 | 16,089 | - | 1.1 | 459 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 78,078 | 78,078 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 469 | 16,492 | - | 5.4 | 2,542 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 402 | 16,961 | - | 7.9 | 3,184 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 402 | 17,363 | - | 7.0 | 2,822 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 402 | 17,765 | - | 8.4 | 3,361 | Common Stock |
| Acrivon Therapeutics Inc | Gamelin Erick | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 45,045 | 45,045 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 468 | 18,167 | - | 3.4 | 1,591 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 60,090 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 20,030 | 20,030 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges